VivoSeq
Ophthalmology

Ocular Onchocerciasis

2

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Ocular Onchocerciasis is an early-stage landscape with 2 programs across 2 companies. The most active players are Medicines Development for Global Health, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Medicines Development for Global Health

1 program

ApprovedC

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Approved

Pipeline

Programs by Phase

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)